Gentium To Initiate Clinical Development in Japan and Expand Named-Patient Program Access to Asia and Japan VILLA GUARDIA (COMO), Italy, December 5, 2012 (GlobeNewswire) – Gentium S.p.A. (NASDAQ: GENT) (the “Company”) today announced the Company’s entry into an agreement with the National University Corporation Hamamatsu University School of Medicine (“HUSM”), Fukushima Medical University (“FMU”) and

Australian-based specialist pharmaceutical and medical technologies business, LINK Healthcare today announced a significant expansion of its operations in the ‘Triple A’ regions of Australasia, Asia and Africa. LINK has completed a series of acquisitions and agreements which have seen it emerge as a multinational operation with annual sales approaching $100m and more than 125 employees.

Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce that it has recently launched in Australia Acetylcysteine-LINK Injection, for the emergency treatment of paracetamol overdose. LINK is collaborating with Martindale Pharma, leaders in the manufacture and supply of specialty pharmaceuticals in the UK, to supply and distribute injectable acetylcysteine under the

EirGen Pharma, currently on an Enterprise Ireland trade mission to South Africa, has secured a significant partnership agreement with South African pharmaceuticals company Equity Pharmaceuticals to develop and commercially supply five oncology products from its Waterford facility. This week’s Enterprise Ireland trade mission to South Africa, where 28 Irish firms are holding meetings with their

LINK Healthcare today announced it had been granted a licence to market Relistor® (methylnaltrexone) in Australia, New Zealand, South Africa and Asia from Salix Pharmaceuticals, Inc. of North Carolina, USA. Relistor subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to

GUARDIA (COMO), Italy, June 15, 2011, (GLOBE NEWSWIRE) — Gentium S.p.A.(NASDAQ: GENT) announced the appointment of LINK Pharmaceuticals as exclusive distributor of Defibrotide in Australia and New Zealand. Under the terms of the agreement, LINK will be responsible for managing named patient requests

Antony (France), 18 May 2011 – Stallergenes S.A. has announced that the Australian health authority, the Therapeutic Goods Administration (TGA), has approved the grass pollen sublingual immunotherapy tablet, Oralair® in adult and pediatric indications. A proven ability to build and sustain an agile sales and marketing solution is ideally suited to specialist pharmaceuticals and medical

LINK Pharma has received marketing approval in both Australia and New Zealand for “ANAPEN 500,” a 500 microgram adrenaline auto-injector. “ANAPEN 500” is approved for adults with a mean body weight of 60kg or more, or adults at high risk of severe anaphylaxis for whom a 300 microgram dose may not be sufficient. Australian and

LINK Pharma has acquired the range of adrenaline products previously sold by Astra Zeneca Australia. The registrations for both 1:1000 and 1:10,000 strength ampoules have been recently transferred. This range is a perfect fit with LINK’S ANAPEN adrenaline auto-injector, which was launched in 2010.

Stallergenes and LINK are pleased to announce the reinforcement of their partnership for the Australian market. Stallergenes has recently created a dedicated Australian affiliate company to work alongside LINK, providing management, medical and marketing support to answer the specific needs of allergy clinicians and patients with allergies.